Executive Summary
The 16 filings from BSE SENSEX 30 constituents reveal a mixed picture for Q1 FY27: revenue growth is broad-based (Trent +18.5%, L&T +7%, Sun Pharma +10.1%, Tata Steel resilient), but margin pressures and operational headwinds are evident.
Trent's like-for-like fashion growth is in the low single digits, Sun Pharma's US sales declined 9.7% YoY due to Lenalidomide erosion, and Tata Steel faces ₹1,200 crore in unplanned cost increases from the West Asia conflict. On the positive side, capital allocation is shareholder-friendly (Trent bonus issue 1:2, L&T merger of subsidiary), and forward-looking catalysts include HCLTech's OpenAI partnership, Infosys's 10-year Crocs deal, and Sun Pharma's Organon acquisition closing by early 2027. Insider activity is limited, but promoter reclassification at Sun Pharma signals governance improvements. The overarching theme is 'growth with caution'—companies are investing in expansion (Tata Steel 4.8 MTPA at NINL, Trent's Tier II/III store openings) while navigating cost inflation and geopolitical uncertainty.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Corporate governance · Company update · Corporate action
Tracking the trend? Catch up on the prior BSE Sensex 30 Stocks Regulatory Filings digest from August 05, 2026.
Investment Signals (12)
- Trent Limited ↓ (BULLISH)▲
Standalone revenue grew 18.5% YoY to ₹5,666 Cr, operating margin expanded 104 bps to 12.92%, and net profit rose 25.8% YoY—outperforming the consumer discretionary sector. Bonus issue 1:2 signals management confidence.
- Larsen & Toubro ↓ (BULLISH)▲
Group order inflows surged 14% YoY to ₹108,014 Cr, with Infrastructure & Utilities orders more than doubling. International orders at 56% of inflow provide geographic diversification. PAT grew 14% YoY.
- Sun Pharmaceutical Industries ↓ (BULLISH)▲
India formulations grew 16% YoY and global innovative medicines grew 12.8% YoY, offsetting US sales decline. Organon acquisition on track for early 2027—a potential catalyst for EPS accretion.
- HCL Technologies ↓ (BULLISH)▲
Named OpenAI Advanced Partner, positioning it to capture enterprise AI adoption. With $14.8B in trailing revenue and 223,000 employees, this partnership could drive high-margin consulting revenue.
- Infosys ↓ (BULLISH)▲
Signed a 10-year strategic agreement with Crocs to modernize core IT using AI-first platforms. Long-term recurring revenue stream with potential for cross-selling.
- Tata Steel ↓ (BULLISH)▲
India EBITDA rose 32% YoY to ₹9,900 Cr with per-ton EBITDA of ₹19,162, demonstrating strong operational leverage. 4.8 MTPA expansion at NINL adds growth optionality.
- Trent Limited ↓ (BEARISH)▲
Like-for-like fashion growth in low single digits—a deceleration from prior quarters. Consolidated share of profit from associates/JV turned to a loss of ₹9.74 Cr vs profit of ₹9.21 Cr YoY.
- Sun Pharmaceutical Industries ↓ (BEARISH)▲
US sales declined 9.7% YoY to USD427 million due to Lenalidomide erosion and generic competition. EBITDA margins slipped to 28.9% from prior year.
- Larsen & Toubro ↓ (BEARISH)▲
Energy – Conventional segment order inflow declined 90% YoY, and Infrastructure & Utilities segment reported a 3% revenue decline with margin contraction.
- Tata Steel ↓ (BEARISH)▲
Unplanned cost increases of ₹1,200 crore from West Asia conflict, with conversion costs up ₹5,400 per ton QoQ. UK and Netherlands operations face supply chain disruptions.
- Trent Limited ↓ (BEARISH)▲
Standalone net profit margin declined to 9.38% from 9.99% YoY, and current ratio weakened to 2.23 from 2.57—indicating tighter liquidity despite revenue growth.
- Sun Pharmaceutical Industries ↓ (BEARISH)▲
Forex gain declined to INR1,220 million from prior year, and exceptional charges of INR1,617 million for Organon acquisition costs will continue in subsequent quarters.
Risk Flags (10)
- Trent/Operational Risk↓ [HIGH RISK]▼
Like-for-like fashion growth in low single digits suggests store expansion is masking underlying demand weakness. Over 80% of new Zudio stores in Tier II/III cities may face lower ticket sizes and higher return risks.
- Sun Pharma/Revenue Concentration Risk↓ [HIGH RISK]▼
US sales declined 9.7% YoY, and Lenalidomide erosion is structural. With Rest of World formulations also marginally lower, the company is overly reliant on India and innovative medicines for growth.
- Tata Steel/Cost Inflation Risk↓ [HIGH RISK]▼
Material costs up ₹1,330 per ton and conversion costs up ₹5,400 per ton QoQ. The ₹1,200 crore unplanned cost increase from West Asia conflict may not fully taper as expected.
- L&T/Segment Risk [MEDIUM RISK]▼
Energy – Conventional order inflow collapsed 90% YoY, and Infrastructure & Utilities revenue declined 3% with margin contraction. Over-reliance on international orders (56% of inflow) exposes to forex and geopolitical risks.
- Trent/JV Risk↓ [MEDIUM RISK]▼
Share of profit from associates/JV turned to a loss of ₹9.74 Cr from a profit of ₹9.21 Cr YoY—a ₹18.95 Cr swing. This could indicate operational issues in joint ventures.
- Sun Pharma/Regulatory Risk↓ [LOW RISK]▼
Promoter reclassification (3 individuals to public) is positive for governance, but the process took 3 months (May to August 2026), suggesting potential regulatory scrutiny.
- Trent/Liquidity Risk↓ [HIGH RISK]▼
Current ratio declined to 2.23 from 2.57 YoY, and debt service coverage ratio dropped sharply to 0.95 from 2.76 QoQ—indicating potential strain on debt servicing capacity.
- Tata Steel/Geographic Risk↓ [MEDIUM RISK]▼
UK and Netherlands operations face headwinds from supply chain disruptions and a temporary Direct Sheet Plant shutdown. India business contributes 75% of production, but international exposure remains a drag.
- L&T/Merger Risk [LOW RISK]▼
Merger of wholly owned subsidiary L&T Power Development into the company may create integration costs and distract from core operations. No financial details disclosed.
- Sun Pharma/Acquisition Risk↓ [MEDIUM RISK]▼
Organon acquisition costs of INR1,617 million in Q1 with additional charges expected. Integration risk and potential dilution if funded via equity.
Opportunities (10)
- Trent/Expansion Play↓ (OPPORTUNITY)◆
Over 80% of new Zudio stores in Tier II/III cities, with emerging categories (beauty & personal care, innerwear, footwear) contributing 21% of revenues. This is a structural growth story in India's consumption upgrade.
- HCLTech/AI Partnership (OPPORTUNITY)◆
OpenAI Advanced Partner status positions HCLTech to capture enterprise AI spending. With $14.8B revenue and global reach, this could drive high-margin consulting and implementation revenue.
- Infosys/Long-Term Deal↓ (OPPORTUNITY)◆
10-year strategic agreement with Crocs provides recurring revenue visibility. AI-first platform modernization is a high-value service that could lead to further deals in the retail sector.
- L&T/Order Book Momentum (OPPORTUNITY)◆
Group order inflows surged 14% YoY to ₹108,014 Cr, with Infrastructure & Utilities orders more than doubling. International orders at 56% of inflow provide diversification. PAT grew 14% YoY.
- Tata Steel/India Expansion↓ (OPPORTUNITY)◆
4.8 MTPA expansion at NINL and India EBITDA up 32% YoY to ₹9,900 Cr with per-ton EBITDA of ₹19,162. India operations are a cash cow funding international turnaround.
- Sun Pharma/Organon Acquisition↓ (OPPORTUNITY)◆
Shareholder approval received, closing by early 2027. This could add significant scale in global markets and diversify revenue away from US generics.
- Trent/Bonus Issue↓ (OPPORTUNITY)◆
1:2 bonus share issuance signals management confidence and improves liquidity. Adjusted EPS still shows strong growth (25.8% YoY).
- Sun Pharma/Governance Improvement↓ (OPPORTUNITY)◆
Promoter reclassification of 3 individuals to public category enhances corporate governance and may attract institutional investors focused on ESG.
- L&T/International Mix (OPPORTUNITY)◆
International revenues at 51% of total and international orders at 56% of inflow provide currency diversification and exposure to global infrastructure spending.
- Tata Steel/Cost Tapering↓ (OPPORTUNITY)◆
Management expects unplanned cost increases of ₹1,200 crore from West Asia conflict to taper in coming quarters. If realized, this could drive margin expansion.
Sector Themes (6)
- Consumption Growth with Margin Pressure◆
Trent's 18.5% revenue growth but low single-digit like-for-like growth indicates that store expansion is driving top line while margins face pressure from input costs and competition. This pattern may be visible across the retail sector.
- AI and Digital Transformation Driving IT Services◆
HCLTech's OpenAI partnership and Infosys's 10-year Crocs deal highlight a shift toward AI-first platforms and long-term strategic engagements. IT services companies are moving from cost arbitrage to value-added partnerships.
- Infrastructure and Energy Transition◆
L&T's order inflow surge (14% YoY) with Infrastructure & Utilities orders doubling and Energy – Green up 58% reflects government and corporate spending on infrastructure and renewable energy. This is a multi-year theme.
- Pharma: US Headwinds vs. Domestic Strength◆
Sun Pharma's US sales decline (-9.7% YoY) contrasts with India formulations growth (+16% YoY). The sector is bifurcating—companies with strong domestic franchises are outperforming those reliant on US generics.
- Steel: Cost Inflation and Geopolitical Uncertainty◆
Tata Steel's ₹1,200 crore unplanned cost increase from West Asia conflict and conversion cost inflation of ₹5,400 per ton QoQ highlight sector-wide input cost pressures. India operations remain a bright spot.
- Capital Allocation: Shareholder-Friendly Actions◆
Trent's bonus issue (1:2) and L&T's subsidiary merger indicate a focus on shareholder returns and simplification. No buybacks or dividends were announced, but these actions signal management confidence.
Watch List (8)
- L&T/Analyst Meetings👁
Five analyst meetings scheduled between August 12 and September 17, 2026. Watch for guidance on order pipeline and margin recovery in Energy – Conventional segment.
-
Participation in Emkay Confluence (Aug 12) and Motilal Oswal Conference (Aug 18-19). Watch for updates on cargo volume guidance and debt reduction plans.
-
Closing expected by early 2027. Watch for regulatory approvals, financing details, and integration milestones in subsequent quarters.
-
Management expects ₹1,200 crore unplanned costs to taper. Watch Q2 FY27 results for evidence of cost normalization and UK/Netherlands operational improvements.
-
Low single-digit like-for-like growth in Q1 is a key metric to monitor. Watch Q2 FY27 for any acceleration or further deceleration, especially in the Zudio format.
-
10-year agreement with Crocs. Watch for initial implementation milestones, revenue contribution, and potential similar deals in the retail sector.
- HCLTech/OpenAI Partnership👁
Named Advanced Partner. Watch for revenue contribution from AI services, partnership expansions, and client wins in the coming quarters.
-
Effective August 6, 2026. Watch for any subsequent insider trading activity by the reclassified individuals and impact on stock liquidity.
Filing Analyses
(16)
06-08-2026
06-08-2026
Trent Limited reported Q1 FY27 standalone revenue from operations of ₹5,666.30 Cr, up 18.5% YoY from ₹4,781.25 Cr in Q1 FY26, and net profit of ₹531.77 Cr, up 25.8% YoY from ₹422.59 Cr. On a consolidated basis, revenue grew 17.8% YoY to ₹5,754.71 Cr, while net profit rose 22.0% to ₹518.07 Cr. However, the company's share of profit from associates/joint ventures turned negative at ₹(9.74) Cr versus a positive ₹9.21 Cr in the prior year quarter, and the consolidated net profit margin declined slightly to 9.00% from 8.70% (standalone) but was lower than the FY26 full-year margin of 9.99%. The Board also approved a change in Head of Internal Audit and recommended the appointment of B S R & Co. LLP as statutory auditors for FY28-32.
- · Standalone operating margin improved to 12.92% in Q1 FY27 from 11.52% in Q1 FY26.
- · Standalone debt-equity ratio improved to 0.29 from 0.34 a year ago.
- · Standalone current ratio declined to 2.23 from 2.57 in the prior year quarter.
- · Standalone inventory turnover ratio was 5.35 vs 5.37 in Q1 FY26, essentially flat.
- · Standalone debtors turnover ratio fell to 303.76 from 402.38 in Q1 FY26.
- · The company issued 1 bonus share for every 2 shares held during the quarter, increasing paid-up equity capital from ₹35.55 Cr to ₹53.32 Cr.
- · Redeemable NCDs of ₹500 Cr (5,000 debentures of ₹10 Lakh each) were fully redeemed on 29th May 2026.
- · Statutory auditors Deloitte Haskins & Sells LLP will retire after the 75th AGM in 2027; B S R & Co. LLP recommended for appointment from FY28 to FY32.
06-08-2026
Trent Limited reported strong Q1 FY27 standalone revenue from operations of ₹5,666.30 Cr, up 18.5% YoY from ₹4,781.25 Cr, and net profit of ₹531.77 Cr, up 25.8% YoY from ₹422.59 Cr. Consolidated revenue from operations grew 17.8% YoY to ₹5,754.71 Cr, while consolidated net profit rose 22.0% YoY to ₹518.07 Cr. However, the company's share of profit from associates/joint ventures turned to a loss of ₹9.74 Cr in Q1 FY27 versus a profit of ₹9.21 Cr in Q1 FY26, and the debt service coverage ratio declined sharply to 0.95 from 2.76 in the prior quarter.
- · The company issued 1 bonus share for every 2 shares held during the quarter, and EPS for all periods has been adjusted accordingly.
- · Standalone operating margin improved to 12.92% in Q1 FY27 from 11.88% in Q1 FY26.
- · Consolidated net profit margin improved to 9.00% in Q1 FY27 from 8.57% in Q1 FY26.
- · Standalone debt equity ratio improved to 0.29 from 0.33 a year ago.
- · Consolidated debt service coverage ratio fell to 0.95 in Q1 FY27 from 2.76 in Q4 FY26.
- · Deloitte Haskins & Sells LLP will retire as statutory auditors after the 75th AGM in 2027; B S R & Co. LLP has been appointed subject to member approval.
- · Ms. Varsha Agarwal will succeed Mr. Ratul Neogi as Head – Internal Audit effective September 1, 2026.
- · Exceptional items of ₹25.79 Cr (standalone) and ₹26.11 Cr (consolidated) for FY ended March 2026 relate to the impact of new labour codes effective November 21, 2025.
06-08-2026
Larsen & Toubro Limited has informed the stock exchanges about its schedule of participation in five analyst and institutional investor meetings between August 12 and September 17, 2026. The company will present at conferences hosted by Emkay, Motilal Oswal, Elara, UBS, and Jefferies, all in in-person mode. No financial results or material developments were disclosed in this filing.
- · Meetings are scheduled on August 12, August 17, September 1, September 10, and September 17, 2026.
- · All meetings are in-person and held in Mumbai or Gurgaon.
- · The presentation will be consistent with the one already available on the company/exchange websites.
06-08-2026
Trent Limited reported Q1FY27 standalone revenue from operations of ₹5,666 Cr, up 19% YoY, with operating EBITDA of ₹847 Cr (+36%), operating EBIT of ₹732 Cr (+33%), and PAT of ₹532 Cr (+26%). Consolidated revenue was ₹5,755 Cr (+18%), with operating EBITDA of ₹848 Cr (+33%), operating EBIT of ₹724 Cr (+29%), and PAT of ₹518 Cr (+22%). However, like-for-like growth for the fashion portfolio was only in the low single digits, and the company noted elevated uncertainties from geo-political events and rising input costs.
- · Like-for-like growth for fashion portfolio in Q1FY27 was in the low single digits.
- · Over 80% of new Zudio stores in Q1FY27 were opened in Tier II, III cities and peripheral micro-markets.
- · Emerging categories (beauty & personal care, innerwear, footwear) contributed over 21% of revenues.
- · Online revenues contributed over 6% of Westside revenues in Q1FY27.
- · Food & grocery (Star) added 5 new stores in Q1FY27, total 86 stores across 12 cities.
- · The company noted rising input costs and geo-political uncertainties, but mitigated through value chain interventions and price architecture calibration.
- · Operating EBIT margin (standalone) was 12.9% in Q1FY27 vs 12.9% in Q1FY26 (flat).
- · PAT margin (standalone) was 9.4% in Q1FY27 vs 8.8% in Q1FY26 (improved).
06-08-2026
Trent Limited reported strong standalone revenue growth of 18.5% YoY to ₹5,666.30 Cr for Q1 FY27 (quarter ended June 30, 2026), with net profit up 25.8% YoY to ₹531.77 Cr. Consolidated revenue grew 17.8% YoY to ₹5,754.71 Cr, while consolidated net profit rose 22.0% YoY to ₹518.07 Cr. However, the company's share of profit from associates/joint ventures turned negative at ₹(9.74) Cr vs. a positive ₹9.21 Cr in the same quarter last year, and the consolidated operating margin (12.92% standalone) showed a slight sequential decline from 11.52% to 12.92% (improved from 11.88% YoY). The board also approved a bonus share issuance (1:2), changes in senior management, and recommended appointment of new statutory auditors.
- · Standalone revenue for Q1 FY27 was ₹5,666.30 Cr vs ₹4,936.64 Cr in Q4 FY26 (sequential growth of 14.8%).
- · Standalone net profit for Q1 FY27 was ₹531.77 Cr vs ₹454.75 Cr in Q4 FY26 (sequential growth of 16.9%).
- · Consolidated revenue for Q1 FY27 was ₹5,754.71 Cr vs ₹5,027.99 Cr in Q4 FY26 (sequential growth of 14.5%).
- · Consolidated net profit for Q1 FY27 was ₹518.07 Cr vs ₹413.10 Cr in Q4 FY26 (sequential growth of 25.4%).
- · Standalone operating margin improved to 12.92% from 11.52% sequentially and 11.88% YoY.
- · Standalone net profit margin declined to 9.38% from 9.99% YoY.
- · Consolidated share of profit from associates/JVs turned negative to ₹(9.74) Cr from positive ₹9.21 Cr YoY.
- · Bonus shares issued in the quarter: 1 bonus share for every 2 shares held.
- · Paid-up equity share capital increased to ₹53.32 Cr from ₹35.55 Cr due to bonus issue.
- · Debt equity ratio improved to 0.29 from 0.34 sequentially.
- · Current ratio declined to 2.23 from 2.57 sequentially.
- · Inventory turnover ratio remained stable at 5.35 vs 5.37 sequentially.
- · Debtors turnover ratio declined to 303.76 from 402.38 sequentially.
- · Exceptional item of ₹25.79 Cr in FY26 related to labour code consolidation.
- · Statutory auditors Deloitte Haskins & Sells LLP to retire after 75th AGM in 2027; B S R & Co. LLP recommended as replacement for 5-year term (FY28-FY32).
- · Head of Internal Audit Mr. Ratul Neogi retiring effective Sept 1, 2026; Ms. Varsha Agarwal appointed as replacement.
06-08-2026
Trent Limited reported Q1 FY27 standalone revenue from operations of ₹5,666.30 crore, up 18.5% YoY from ₹4,781.25 crore, and consolidated revenue of ₹5,754.71 crore, up 17.8% YoY. Standalone net profit rose 25.8% YoY to ₹531.77 crore, while consolidated net profit grew 22.0% to ₹518.07 crore. However, consolidated share of profit from associates/joint ventures turned to a loss of ₹9.74 crore versus a profit of ₹9.21 crore in the prior year. The Board also approved the appointment of B S R & Co. LLP as statutory auditors for FY2027-28 to FY2031-32, and announced changes in senior managerial personnel.
- · Standalone operating margin improved to 12.92% in Q1 FY27 from 11.88% in Q1 FY26.
- · Standalone net profit margin declined to 9.38% in Q1 FY27 from 9.99% in Q1 FY26.
- · Consolidated share of profit from associates/JV turned to a loss of ₹9.74 crore in Q1 FY27 from a profit of ₹9.21 crore in Q1 FY26.
- · The company issued 1 bonus share for every 2 shares held during the quarter.
- · Redeemable NCDs of ₹5000 crore (face value ₹10 lakh each) were redeemed on 29th May 2026.
- · Mr. Ratul Neogi will retire as Head of Internal Audit effective 1st September 2026; Ms. Varsha Agarwal appointed as his replacement.
- · Deloitte Haskins & Sells LLP will retire as statutory auditors after the 75th AGM in 2027; B S R & Co. LLP recommended for appointment for FY2027-28 to FY2031-32.
06-08-2026
Tata Steel reported a resilient Q1 FY2027 performance with consolidated revenues of ₹60,794 crore and EBITDA of ₹9,370 crore, driven by strong India operations. India EBITDA rose 32% YoY to ₹9,900 crore with a per-ton EBITDA of ₹19,162, while the UK and Netherlands faced headwinds from supply chain disruptions and a temporary Direct Sheet Plant shutdown. The company also announced a 4.8 MTPA expansion at NINL and noted that unplanned cost increases of ₹1,200 crore from the West Asia conflict are expected to taper in coming quarters.
- · India business contributed 75% of total crude steel production.
- · Standalone revenue per ton increased by ₹9,212 QoQ, partly offset by cost increase of ₹6,700 per ton due to lower volumes.
- · Material costs up ₹1,330 per ton; conversion costs up ₹5,400 per ton QoQ.
- · NINL EBITDA margin improved from 27% in Q4 to 29% in Q1.
- · UK reduced tariff-free import quotas by 3.3–3.4 million tons effective July 1, with 50% tariff on excess.
- · Netherlands Direct Sheet Plant (20% of production) shut since April; approval for 4-week run from August 5.
- · Tata Steel has ~50% market share in the Indian automotive sector.
- · Digital platforms Aashiyana and DigECA combined GMV ₹2,200 crore, up 61% YoY.
- · Board approved 4.8 MTPA expansion at NINL, taking total capacity to ~6.2 MTPA.
- · Unplanned cost increases of ₹1,200 crore due to West Asia conflict expected to taper.
06-08-2026
Sun Pharma reported Q1 FY27 consolidated sales of INR151,836 million, up 10.1% YoY, driven by 16% growth in India formulations and 12.8% growth in global innovative medicines. However, U.S. sales declined 9.7% YoY to USD427 million due to Lenalidomide erosion and generic competition, and EBITDA margins slipped to 28.9% from a year ago (adjusted higher excluding prior-year Lenalidomide benefit). The Organon acquisition received shareholder approval and is on track to close by early 2027, with integration planning underway.
- · Rest of World formulations revenue was marginally lower YoY at USD218 million.
- · Forex gain for Q1 FY27 was INR1,220 million, lower than Q1 FY26.
- · Exceptional items include INR1,617 million charge for Organon acquisition costs; additional charges expected in subsequent quarters.
- · Effective tax rate rose to 27.8% from 24.3% in Q1 FY26 due to exhaustion of lower India tax rate.
- · Innovative R&D accounted for 30% of total R&D spend of INR8,264 million.
- · Philogen has resubmitted Nidlegy for marketing authorization in Europe.
- · Sun Pharma is the only company in India offering semaglutide auto-injector.
- · Leqselvi surpassed 1,000 prescribers in June 2026 and delivered strongest month since launch.
- · Unloxcyt shows month-over-month growth as more cancer centers add it to formularies.
- · Sun Pharma holds 8.5% market share in the Indian pharmaceutical market (MAT June 2026), up from 8.2%.
- · Sun Pharma's volume growth of 5.4% compares favorably to IPM volume growth of 2%.
- · The company launched five new products in India and five generic products in the U.S. during Q1 FY27.
06-08-2026
Maruti Suzuki India Limited (MSIL) informed stock exchanges that the transcript of its investors' call held on July 31, 2026, regarding financial results for the quarter ended June 30, 2026, has been uploaded on its website. This is a routine disclosure providing access to the call transcript; no specific financial figures or performance data are included in this filing.
- · The investors' call was held on 31st July 2026.
- · The transcript is accessible at: https://www.marutisuzuki.com/corporate/investors/company-updates.
06-08-2026
HCLTech has been named an OpenAI Advanced Partner, reflecting its strategic collaboration with OpenAI to help enterprises build, deploy, and scale AI-native solutions. The partnership aims to move clients from AI pilots to measurable business impact, leveraging HCLTech's AI expertise and the OpenAI Partner Network. No financial terms or quantitative metrics were disclosed in the announcement.
- · HCLTech has been named an OpenAI Advanced Partner.
- · Consolidated revenues for 12 months ending June 2026: $14.8 billion.
- · HCLTech employs more than 223,000 people across 60 countries.
- · HCLTech is expanding its OpenAI Agentic Transformation Studio to help enterprises build, govern and scale AI.
06-08-2026
Trent Limited granted 20,000 stock options to eligible employees under the 'Trent Limited - Employee Stock Option Plan 2026' at an exercise price of ₹2,652 per share. The grant was approved by the Nomination and Remuneration Committee on August 6, 2026, following shareholder approval via postal ballot on May 27, 2026. No options have vested or been exercised as of the filing date.
- · The options are exercisable into up to 20,000 equity shares of face value ₹1 each.
- · Options will vest after a vesting period at the discretion of the Nomination and Remuneration Committee, subject to performance conditions.
- · Once vested, options must be exercised within a maximum period of one year from the vesting date.
- · No options have vested, been exercised, or lapsed as of the filing date.
06-08-2026
Infosys has entered into a ten-year strategic agreement with Crocs, Inc. to modernize the footwear company's core IT and business systems using AI-first platforms. The collaboration aims to simplify operations, reduce costs, and enable scalable global growth for Crocs. No financial terms of the deal were disclosed.
- · The agreement is for ten years.
- · Infosys will apply its AI-first platforms to modernize Crocs, Inc.'s core business and IT systems.
- · Crocs, Inc. brands include Crocs and HEYDUDE, with products sold in more than 85 countries.
- · Infosys has over 325,000 employees and operates in 59 countries.
06-08-2026
Adani Ports and Special Economic Zone Limited has informed the exchanges that it will interact with institutional investors and analysts at two conferences in Mumbai in August 2026: Emkay Confluence 2026 on August 12, and Motilal Oswal 22nd Annual Conference 2026 on August 18-19. The presentation for the meetings has been uploaded on the company's website. This is a routine disclosure under Regulation 30 and contains no financial results or material business developments.
- · The company will participate in Emkay Confluence 2026 on August 12, 2026 (physical, Mumbai).
- · The company will participate in Motilal Oswal 22nd Annual Conference 2026 on August 18-19, 2026 (physical, Mumbai).
- · Dates are subject to change due to exigencies on the part of investors/company.
- · The presentation for the meetings is available on the company's website www.adaniports.com.
07-08-2026
Larsen & Toubro reported consolidated revenues of ₹ 67,942 crore for Q1 FY27, up 7% YoY, and PAT of ₹ 4,123 crore, up 14% YoY. Group order inflows surged 14% to ₹ 108,014 crore, driven by strong performance in Infrastructure & Utilities (order inflow more than doubled) and Energy – Green (+58%). However, the Energy – Conventional segment saw a 90% decline in order inflows, and the Infrastructure & Utilities segment reported a 3% revenue decline with margin contraction. The Board also approved the merger of wholly owned subsidiary L&T Power Development Limited into the company.
- · International revenues contributed 51% of total revenues at ₹ 34,393 crore.
- · International orders constituted 56% of total order inflow at ₹ 60,702 crore.
- · International orders made up 52% of the overall order book.
- · Infrastructure & Utilities segment order inflow more than doubled YoY, but revenue declined 3% and EBITDA margin contracted from 5.5% to 5.1%.
- · Energy – Conventional segment order inflow plunged 90% YoY due to deferment of anticipated orders and a high base effect.
- · Energy – Green segment revenue fell 11% YoY due to supply chain disruptions from the West Asia conflict.
- · Manufacturing & Products segment EBITDA margin dropped from 17.5% to 15.2% due to a change in sales mix.
- · Technology, Platforms & Services segment EBITDA margin edged down from 19.5% to 19.2% due to higher manpower costs and forex variation.
- · The Board approved the merger of wholly owned subsidiary L&T Power Development Limited into the company, subject to NCLT approval.
- · The company concluded the sale of Nabha Power Limited and signed a share purchase agreement to divest 100% stake in Hyderabad Metro SPV.
- · No funds were raised during the quarter, and no secured non-convertible debentures were outstanding.
06-08-2026
Sun Pharmaceutical Industries Ltd received no-objection letters from NSE and BSE on August 6, 2026, for reclassification of three individuals—Krishna Vrundavandas Valia, Sudhir Vrundavandas Valia, and Raksha Sudhir Valia—from the 'Promoter Group' category to the 'Public' category under SEBI Listing Regulations. This regulatory approval follows earlier intimations in May 2026 and does not involve any financial figures or performance metrics.
- · The reclassification application was initially made on May 26, 2026, and the company had previously intimated the exchanges on May 14, May 22, and May 26, 2026.
- · The no-objection letters were issued by NSE (Ref: NSE/LIST/COMP/SUNPHARMA/600/2026-2027) and BSE (Ref: LIST/COMP /KR/163/2026-27) on August 6, 2026.
- · The reclassification is in accordance with Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 16 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: BSE Sensex 30 Stocks Regulatory Filings
🇮🇳 More from India
View all →August 06, 2026
India Pre-Market Regulatory Roundup — August 06, 2026
India Pre-Market Regulatory Roundup
August 06, 2026
India Quarterly Results BSE NSE Announcements — August 06, 2026
India Quarterly Results BSE NSE Announcements
August 06, 2026
India Upcoming Corporate Actions BSE NSE — August 06, 2026
India Upcoming Corporate Actions BSE NSE
August 06, 2026
India Merger Acquisition MCA Regulatory Filings — August 06, 2026
India Merger Acquisition MCA Regulatory Filings